CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Sensei Biotherapeutics, Inc. (FTH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Sensei Biotherapeutics, Inc. (FTH)

Pharmaceutical Preparations · market cap $844M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-31 (est.)
Regulatory
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
  • 2026-12-31 (est.)Regulatoryimp 6/10
Pipeline
AssetPhaseIndication
SNS-101 (anti-VISTA)Phase 2Solid Tumor, Adult
Price & technical context
3-month
-71.1%
6-month
-52.1%
12-month
+5.7%
52-wk range
$7.89–$40.05
vs 50-day MA
-61.0%
vs 200-day MA
-62.5%
Realized vol
164.3%
Max drawdown
-76.2%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for FTH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.